-58.1%
CLSK vs MRNA
+945.0%
-1,003.1%
-63.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -16.6% | +13.1% | -29.7% | -17.0% |
| 7D | -20.7% | +20.6% | -41.4% | -21.4% |
| 30D | -45.5% | +27.1% | -72.7% | -46.1% |
| 3M | -52.0% | +353.4% | -405.4% | -57.9% |
| 6M | -47.0% | +446.3% | -493.2% | -58.6% |
| YTD | -32.8% | +776.2% | -809.0% | -58.9% |
| 1Y | -58.1% | +987.9% | -1,046.0% | -77.3% |
| All | -58.1% | +945.0% | -1,003.1% | -77.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling